This company has been marked as potentially delisted and may not be actively trading. NASDAQ:PRNB Principia Biopharma (PRNB) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Principia Biopharma Stock (NASDAQ:PRNB) 30 days 90 days 365 days Advanced Chart Get Principia Biopharma alerts:Sign Up Key Stats Today's Range$100.05▼$100.0550-Day Range$99.95▼$100.2752-Week Range$25.35▼$101.89VolumeN/AAverage Volume729,676 shsMarket Capitalization$3.32 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Principia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology. The company is developing PRN1008, an inhibitor that is in Phase III clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial to treat immune thrombocytopenic purpura. It is also developing PRN2246/SAR442168, an inhibitor, which has completed Phase I clinical trial for treating multiple sclerosis (MS) and other central nervous system (CNS) diseases; PRN1371, a drug candidate that is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California. Read More Receive PRNB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Principia Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address PRNB Stock News HeadlinesSports Final: Maty Mauk ready to coach Principia High SchoolApril 25, 2025 | msn.comFORE Biotherapeutics Names Michael Byrnes as Chief Financial OfficerAugust 12, 2024 | finance.yahoo.comI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.July 4 at 2:00 AM | Porter & Company (Ad)Principia College names new presidentMay 28, 2023 | bizjournals.comCBI appoints ethics consultancy Principia Advisory in fight for survivalMay 5, 2023 | theguardian.comTruist Securities Downgrades 9 Meters Biopharma to Hold, Announces $38 Price TargetMarch 22, 2023 | benzinga.comWooly mammoth tusk discovered on Principia College campusJanuary 17, 2023 | msn.comDodge Construction Network Acquires Principia Consulting, Expanding Dodge Advisory Services’ CapabilitiesOctober 12, 2022 | finance.yahoo.comSee More Headlines PRNB Stock Analysis - Frequently Asked Questions How were Principia Biopharma's earnings last quarter? Principia Biopharma Inc. (NASDAQ:PRNB) posted its earnings results on Thursday, August, 6th. The company reported $0.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.03) by $1.34. The firm had revenue of $50 million for the quarter, compared to analyst estimates of $50 million. When did Principia Biopharma IPO? Principia Biopharma (PRNB) raised $75 million in an initial public offering (IPO) on Friday, September 14th 2018. The company issued 4,700,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, Leerink Partners and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager. What other stocks do shareholders of Principia Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Principia Biopharma investors own include Pfizer (PFE), Advanced Micro Devices (AMD), AbbVie (ABBV), Bristol Myers Squibb (BMY), Cisco Systems (CSCO), QUALCOMM (QCOM) and VBI Vaccines (VBIV). Company Calendar Last Earnings8/06/2020Today7/04/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:PRNB CIKN/A Webwww.principiabio.com Phone650-416-7700FaxN/AEmployees65Year FoundedN/AProfitability EPS (Trailing Twelve Months)($2.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$53.79 million Net MarginsN/A Pretax MarginN/A Return on Equity-23.08% Return on Assets-21.11% Debt Debt-to-Equity RatioN/A Current Ratio17.01 Quick Ratio17.01 Sales & Book Value Annual Sales$35.16 million Price / Sales94.50 Cash FlowN/A Price / Cash FlowN/A Book Value$10.95 per share Price / Book9.14Miscellaneous Outstanding Shares33,209,000Free FloatN/AMarket Cap$3.32 billion OptionableNot Optionable Beta0.86 The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:PRNB) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredRevealed: NEW A.I. revolution (nobody is talking about)Nvidia's CEO says this is: "The next wave of A.I." We're at the cusp of a new "A.I. Upgrade" that is set to...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Principia Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Principia Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.